GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF

GRI Bio, Inc.

2026-Q1 EPS reported -$1.61 vs consensus -$0.91 ▼ miss (-76.1%)

Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.
Phase 2a of GRI-0621 in IPF: zero cough in active arm vs 25% placebo; 61% less diarrhea vs placebo despite 67% more nintedanib use.
Exploratory FVC improvement: +99 mL overall, +139 mL in SOC combination subset vs placebo+SOC.
Raised ~$6.8M gross via ATM facility in Q1 2026; advancing GRI-0621 toward pivotal studies, GRI-0803 toward IND.
No SAEs in active arm; single SAE in placebo; patent applications filed based on new data.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GRI Bio, Inc. reported three months ended March 31, 2026 results: net income approximately $2.0 million.

Period: three months ended March 31, 2026
Net income: approximately $2.0 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025.

View on SEC.gov

Browse all earnings releases →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-26-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.